HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

F Pillard Selected Research

Anemia

5/2013High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


F Pillard Research Topics

Disease

2Overweight
06/2012 - 11/2003
2Sarcopenia
10/2009 - 08/2008
1Anemia
05/2013
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
05/2013
1Hepatitis C
01/2009
1Cognitive Dysfunction
11/2005
1Obesity
11/2003

Drug/Important Bio-Agent (IBA)

1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
05/2013
1ErythropoietinFDA Link
05/2013
1HematinicsIBA
05/2013
1Filgrastim (Neupogen)FDA Link
05/2013
1Darbepoetin alfa (Aranesp)FDA Link
05/2013
1CarbohydratesIBA
06/2012
1Hormones (Hormone)IBA
10/2009
1Proteins (Proteins, Gene)FDA Link
10/2009
1InterferonsIBA
01/2009
1Ribavirin (Virazole)FDA LinkGeneric
01/2009
1Muscle Proteins (Muscle Protein)IBA
08/2008
1Nonesterified Fatty Acids (NEFA)IBA
11/2003
1LipidsIBA
11/2003

Therapy/Procedure

1Denervation
10/2009
1Resistance Training
10/2009
1Therapeutics
01/2009
1Activities of Daily Living (ADL)
11/2005
1Endurance Training
11/2003